Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma
1 other identifier
observational
1
0 countries
N/A
Brief Summary
The study population was selected from high grade glioma pateints attending the Department of Clinical Oncology, Assiut University hospital during the period from December 2018 to September 2020, we analyzed human high grade gliomas paraffin block for FLG2 expression
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Nov 2019
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 1, 2019
CompletedFirst Posted
Study publicly available on registry
October 2, 2019
CompletedStudy Start
First participant enrolled
November 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2021
CompletedOctober 2, 2019
October 1, 2019
10 months
October 1, 2019
October 1, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Rple of FGL2in high grade glioma as aprognostic factor
Correlation between FLG2 expression and progression free survival and overall survival
baseline
Interventions
Correlation between FLG2 expression and progression free survival and overall surviv
Eligibility Criteria
The study population was selected from high grade glioma pateints attending the Department of Clinical Oncology, Assiut University hospital during the period from December 2018 to September 2020, we analyzed human high grade gliomas paraffin block for FLG2 expression
You may qualify if:
- Pateints\>18 years old
- Pathologically proven high grade glioma
- Total or subtotal resection of the tumor
- Patients received concurrent radiation therapy with temozolomide followed by adjuvant temozolamide for 6 months
You may not qualify if:
- Pregnancy
- Breast feeding
- Other comorbidity
- Previous malignancy or radiation therapy or chemotherapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- sohaila Essamlead
Related Publications (2)
Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Eric Davis R, Huang S, Fuller GN, Rao A, Heimberger AB, Li S, Rao G. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. J Natl Cancer Inst. 2019 Mar 1;111(3):292-300. doi: 10.1093/jnci/djy107.
PMID: 29947810BACKGROUNDYan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li S. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat Commun. 2019 Jan 25;10(1):448. doi: 10.1038/s41467-018-08271-x.
PMID: 30683885BACKGROUND
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Role of fibrinogen like protein 2 as aprognostic factor in high grade glioma
Study Record Dates
First Submitted
October 1, 2019
First Posted
October 2, 2019
Study Start
November 1, 2019
Primary Completion
September 1, 2020
Study Completion
September 1, 2021
Last Updated
October 2, 2019
Record last verified: 2019-10